RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
RegeneRx Biopharmaceuticals Stock

RegeneRx Biopharmaceuticals ROCE 2024

RegeneRx Biopharmaceuticals ROCE

0.41

Ticker

RGRX

ISIN

US75886X1081

WKN

875295

In 2024, RegeneRx Biopharmaceuticals's return on capital employed (ROCE) was 0.41, a -31.7% increase from the 0.6 ROCE in the previous year.

RegeneRx Biopharmaceuticals Aktienanalyse

What does RegeneRx Biopharmaceuticals do?

RegeneRx Biopharmaceuticals Inc is a biotechnology company focused on the development and commercialization of drugs for the treatment of diseases. The company is headquartered in Rockville, Maryland and was founded in 1982. Since its inception, RegeneRx has brought various products to market and is known for its research in tissue regeneration. The company started its early years with research in the field of nerve regeneration. As a result of this research, RegeneRx developed its first chemical called Thymosin beta 4 (Tβ4). Tβ4 is a naturally occurring protein produced in the human body. It serves as a growth factor for cells and plays an important role in healing damaged tissue. RegeneRx used this knowledge and began intensive work on the growth of Tβ4 in the laboratory. The company's researchers soon realized that Tβ4 was not only important for nerve regeneration, but could also be used in skin damage, stroke, and heart attack treatment. The researchers continued to work on the substance and in 1999 successfully brought the so-called Eye Drop product A3G12 to the market. This product is used to treat eye injuries and infections. In the following years, RegeneRx continued to research Tβ4. It was found that Tβ4 could also be successfully used in COPD (Chronic Lung Problems), wound healing, and bone disorders. Various products were developed for this purpose, available under the names RGN-137, RGN-259, and RGN-352. RegeneRx has also formed partnerships with other pharmaceutical companies such as Axio Biosolutions and Gtree BNP, and has successfully collaborated with them. In early 2021, it was decided that RegeneRx would expand its expertise in the Asian market and signed an agreement with Gtree BNP. The two companies planned to market RegeneRx products RGN-503 and RGN-352 in South Korea. Overall, RegeneRx Biopharmaceuticals Inc. has developed an impressive list of products that have successfully undergone patent and regulatory processes. These products treat a variety of diseases and injuries. RegeneRx is committed to continuing its research in this field and developing new products to help improve the health and well-being of patients worldwide. The company's business model primarily focuses on research and development. It has expanded in recent years due to the high potential of Tβ4 and its use in many medical areas. RegeneRx expects that by expanding the use of Tβ4, there will be greater acceptance and demand for its products worldwide. RegeneRx Biopharmaceuticals Inc is a company operating in the field of regenerative medicine. The products are typically positioned in the higher price range, in line with the company's market positioning. The company has successfully collaborated with other pharmaceutical companies in the past and is expected to form further alliances. RegeneRx sees itself as a leading biotechnology company focused on innovative drugs. RegeneRx Biopharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling RegeneRx Biopharmaceuticals's Return on Capital Employed (ROCE)

RegeneRx Biopharmaceuticals's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing RegeneRx Biopharmaceuticals's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

RegeneRx Biopharmaceuticals's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in RegeneRx Biopharmaceuticals’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about RegeneRx Biopharmaceuticals stock

What is the ROCE (Return on Capital Employed) of RegeneRx Biopharmaceuticals this year?

The ROCE of RegeneRx Biopharmaceuticals is 0.41 undefined this year.

How has the ROCE (Return on Capital Employed) of RegeneRx Biopharmaceuticals developed compared to the previous year?

The ROCE of RegeneRx Biopharmaceuticals has increased by -31.7% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of RegeneRx Biopharmaceuticals?

A high Return on Capital Employed (ROCE) indicates that RegeneRx Biopharmaceuticals has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of RegeneRx Biopharmaceuticals?

A low ROCE (Return on Capital Employed) can indicate that RegeneRx Biopharmaceuticals has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from RegeneRx Biopharmaceuticals impact the company?

An increase in the ROCE of RegeneRx Biopharmaceuticals can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of RegeneRx Biopharmaceuticals affect the company?

A decrease in ROCE of RegeneRx Biopharmaceuticals can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of RegeneRx Biopharmaceuticals?

Some factors that can affect RegeneRx Biopharmaceuticals's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of RegeneRx Biopharmaceuticals so important for investors?

The ROCE of RegeneRx Biopharmaceuticals is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can RegeneRx Biopharmaceuticals take to improve the ROCE?

To improve the ROCE, RegeneRx Biopharmaceuticals can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does RegeneRx Biopharmaceuticals pay?

Over the past 12 months, RegeneRx Biopharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, RegeneRx Biopharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of RegeneRx Biopharmaceuticals?

The current dividend yield of RegeneRx Biopharmaceuticals is .

When does RegeneRx Biopharmaceuticals pay dividends?

RegeneRx Biopharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of RegeneRx Biopharmaceuticals?

RegeneRx Biopharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of RegeneRx Biopharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is RegeneRx Biopharmaceuticals located?

RegeneRx Biopharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von RegeneRx Biopharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of RegeneRx Biopharmaceuticals from 10/7/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/7/2024.

When did RegeneRx Biopharmaceuticals pay the last dividend?

The last dividend was paid out on 10/7/2024.

What was the dividend of RegeneRx Biopharmaceuticals in the year 2023?

In the year 2023, RegeneRx Biopharmaceuticals distributed 0 USD as dividends.

In which currency does RegeneRx Biopharmaceuticals pay out the dividend?

The dividends of RegeneRx Biopharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von RegeneRx Biopharmaceuticals

Our stock analysis for RegeneRx Biopharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of RegeneRx Biopharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.